172 related articles for article (PubMed ID: 19235857)
1. Multivalent interactions with gp120 are required for the anti-HIV activity of Cyanovirin.
Liu Y; Carroll JR; Holt LA; McMahon J; Giomarelli B; Ghirlanda G
Biopolymers; 2009; 92(3):194-200. PubMed ID: 19235857
[TBL] [Abstract][Full Text] [Related]
2. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.
Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G
Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873
[TBL] [Abstract][Full Text] [Related]
3. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120.
Bewley CA; Otero-Quintero S
J Am Chem Soc; 2001 May; 123(17):3892-902. PubMed ID: 11457139
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants.
Chang LC; Bewley CA
J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763
[TBL] [Abstract][Full Text] [Related]
5. A flexible docking scheme efficiently captures the energetics of glycan-cyanovirin binding.
Bolia A; Woodrum BW; Cereda A; Ruben MA; Wang X; Ozkan SB; Ghirlanda G
Biophys J; 2014 Mar; 106(5):1142-51. PubMed ID: 24606938
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120.
Bewley CA
Structure; 2001 Oct; 9(10):931-40. PubMed ID: 11591348
[TBL] [Abstract][Full Text] [Related]
7. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
8. Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity.
Barrientos LG; Lasala F; Delgado R; Sanchez A; Gronenborn AM
Structure; 2004 Oct; 12(10):1799-807. PubMed ID: 15458629
[TBL] [Abstract][Full Text] [Related]
9. Solution and crystal molecular dynamics simulation study of m4-cyanovirin-N mutants complexed with di-mannose.
Vorontsov II; Miyashita O
Biophys J; 2009 Nov; 97(9):2532-40. PubMed ID: 19883596
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1-2)Man provides a basis for anti-HIV activity with low toxicity.
Shahzad-ul-Hussan S; Gustchina E; Ghirlando R; Clore GM; Bewley CA
J Biol Chem; 2011 Jun; 286(23):20788-96. PubMed ID: 21471192
[TBL] [Abstract][Full Text] [Related]
11. Solution and crystal structures of a sugar binding site mutant of cyanovirin-N: no evidence of domain swapping.
Matei E; Furey W; Gronenborn AM
Structure; 2008 Aug; 16(8):1183-94. PubMed ID: 18682220
[TBL] [Abstract][Full Text] [Related]
12. A Designed "Nested" Dimer of Cyanovirin-N Increases Antiviral Activity.
Woodrum BW; Maxwell J; Allen DM; Wilson J; Krumpe LR; Bobkov AA; Hill RB; Kibler KV; O'Keefe BR; Ghirlanda G
Viruses; 2016 Jun; 8(6):. PubMed ID: 27275831
[TBL] [Abstract][Full Text] [Related]
13. The antiviral lectin cyanovirin-N: probing multivalency and glycan recognition through experimental and computational approaches.
Woodrum BW; Maxwell JD; Bolia A; Ozkan SB; Ghirlanda G
Biochem Soc Trans; 2013 Oct; 41(5):1170-6. PubMed ID: 24059504
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization.
Matei E; Zheng A; Furey W; Rose J; Aiken C; Gronenborn AM
J Biol Chem; 2010 Apr; 285(17):13057-65. PubMed ID: 20147291
[TBL] [Abstract][Full Text] [Related]
15. The role of Glu41 in the binding of dimannose to P51G-m4-CVN.
Ramadugu SK; Li Z; Kashyap HK; Margulis CJ
Biochemistry; 2014 Mar; 53(9):1477-84. PubMed ID: 24524298
[TBL] [Abstract][Full Text] [Related]
16. Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.
Parajuli B; Acharya K; Bach HC; Parajuli B; Zhang S; Smith AB; Abrams CF; Chaiken I
Biochem J; 2018 Mar; 475(5):931-957. PubMed ID: 29343613
[TBL] [Abstract][Full Text] [Related]
17. Rational and computational design of stabilized variants of cyanovirin-N that retain affinity and specificity for glycan ligands.
Patsalo V; Raleigh DP; Green DF
Biochemistry; 2011 Dec; 50(49):10698-712. PubMed ID: 22032696
[TBL] [Abstract][Full Text] [Related]
18. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides.
Botos I; O'Keefe BR; Shenoy SR; Cartner LK; Ratner DM; Seeberger PH; Boyd MR; Wlodawer A
J Biol Chem; 2002 Sep; 277(37):34336-42. PubMed ID: 12110688
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate recognition by the antiviral lectin cyanovirin-N.
Fujimoto YK; Green DF
J Am Chem Soc; 2012 Dec; 134(48):19639-51. PubMed ID: 23057413
[TBL] [Abstract][Full Text] [Related]
20. Cyanovirin-N: a sugar-binding antiviral protein with a new twist.
Botos I; Wlodawer A
Cell Mol Life Sci; 2003 Feb; 60(2):277-87. PubMed ID: 12678493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
